Excited to announce the appointment of Jay Fine, Ph.D., as President of R&D. His experience in precision #immunology and translational science will guide the rapid progression of our pipeline of first-in-category, multifunctional #cancer therapeutics.
evolveimmune.com/evolveimmune-t…
evolveimmune.com EvolveImmune Therapeutics Appoints Jay Fine, Ph.D., as President of Research and Development -... EvolveImmune is pioneering a pipeline of unique trispecific T cell engagers with integrated CD2 costimulation. The EVOLVE platform tackles the treatment challenges of cancer cell resistance to... evolveimmune.com/evolveimmune-t…
